# Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT05938920** · PHASE2 · COMPLETED · sponsor: **InSilico Medicine Hong Kong Limited** · enrollment: 71 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** INS018_055
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05938920
- **Lead sponsor:** InSilico Medicine Hong Kong Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-19
- **Primary completion:** 2024-08-08
- **Final completion:** 2024-08-08
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938920, "Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05938920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*